[HTML][HTML] DEAD-box helicase DP103 defines metastatic potential of human breast cancers
EM Shin, HS Hay, MH Lee, JN Goh… - The Journal of …, 2014 - Am Soc Clin Investig
The Journal of clinical investigation, 2014•Am Soc Clin Investig
Despite advancement in breast cancer treatment, 30% of patients with early breast cancers
experience relapse with distant metastasis. It is a challenge to identify patients at risk for
relapse; therefore, the identification of markers and therapeutic targets for metastatic breast
cancers is imperative. Here, we identified DP103 as a biomarker and metastasis-driving
oncogene in human breast cancers and determined that DP103 elevates matrix
metallopeptidase 9 (MMP9) levels, which are associated with metastasis and invasion …
experience relapse with distant metastasis. It is a challenge to identify patients at risk for
relapse; therefore, the identification of markers and therapeutic targets for metastatic breast
cancers is imperative. Here, we identified DP103 as a biomarker and metastasis-driving
oncogene in human breast cancers and determined that DP103 elevates matrix
metallopeptidase 9 (MMP9) levels, which are associated with metastasis and invasion …
Despite advancement in breast cancer treatment, 30% of patients with early breast cancers experience relapse with distant metastasis. It is a challenge to identify patients at risk for relapse; therefore, the identification of markers and therapeutic targets for metastatic breast cancers is imperative. Here, we identified DP103 as a biomarker and metastasis-driving oncogene in human breast cancers and determined that DP103 elevates matrix metallopeptidase 9 (MMP9) levels, which are associated with metastasis and invasion through activation of NF-κB. In turn, NF-κB signaling positively activated DP103 expression. Furthermore, DP103 enhanced TGF-β–activated kinase-1 (TAK1) phosphorylation of NF-κB–activating IκB kinase 2 (IKK2), leading to increased NF-κB activity. Reduction of DP103 expression in invasive breast cancer cells reduced phosphorylation of IKK2, abrogated NF-κB–mediated MMP9 expression, and impeded metastasis in a murine xenograft model. In breast cancer patient tissues, elevated levels of DP103 correlated with enhanced MMP9, reduced overall survival, and reduced survival after relapse. Together, these data indicate that a positive DP103/NF-κB feedback loop promotes constitutive NF-κB activation in invasive breast cancers and activation of this pathway is linked to cancer progression and the acquisition of chemotherapy resistance. Furthermore, our results suggest that DP103 has potential as a therapeutic target for breast cancer treatment.
The Journal of Clinical Investigation